Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells ...

SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company ...

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...

DelveInsight’s, “Gastric Cancer Pipeline Insight” report provides comprehensive insights about 200+ companies and 220+ ...